ADC Conjugation
Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products
in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
ADC
(Antibody Drug Conjugate)
LOTTE BIOLOGICS has committed to the investment of $80 million for the establishment of an ADC facility within the Syracuse Bio Campus.
The expansion is expected to be completed by Q4 2024, with GMP approval being targeted for Q1 2025.
This campus is designed to enable the production of clinical and commercial ADC products. Our staff has over 18 years of experience in DS manufacturing for antibody/protein production, enabling the provision of flexible and optimized manufacturing services for successful ADC conjugation.
DS Manufacturing
- Flexible and optimized manufacturing
- 18+ years of producing antibodies/proteins
- 120+ batches / year
- 62+ approvals by Health Authorities worldwide
- Scale-up, process development, analytical testing
ADC Platform Development
LOTTE BIOLOGICS plans to establish a service dedicated to offering platform technology for ADC through joint development with Kanaph Therapeutics.
This platform is expected to improve conjugation yield and stability through enhanced solubility, as well as being able to accommodate multiple linkers and payloads.
Also, LOTTE BIOLOGICS partners with NJ Bio to provide optimized ADC services with process/analytical capabilities and linker-payload synthesis.
LOTTE BIOLOGICS plans to provide ADC one-stop service in the Syracuse Bio Campus.